Vivos Therapeutics (VVOS) Return on Equity (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Return on Equity data on file, last reported at 0.19% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.19%, up 21.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.19% (up 21.0% YoY), and the FY2025 annual result was 0.07%, down 4.0% from the prior year.
• Return on Equity climbed to 0.19% in Q1 2026 per VVOS's latest filing, from 0.43% in the prior quarter.
• Over five years, Return on Equity peaked at 0.19% in Q1 2026 and troughed at 0.43% in Q4 2025.
• A 5-year average of 0.04% and a median of 0.02% in 2022 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2025 and 2026: Return on Equity tumbled 42 bps in 2025, then rose 21 bps in 2026.
• A 5-year view of Return on Equity shows it stood at 0.03% in 2022, then soared by 106 bps to 0.0% in 2023, then tumbled by 862 bps to 0.01% in 2024, then sank by 2917 bps to 0.43% in 2025, then soared by 143 bps to 0.19% in 2026.
• Business Quant data shows VVOS's Return on Equity at 0.19% in Q1 2026, 0.43% in Q4 2025, and 0.05% in Q3 2025.